Table 3. Table of screened compounds which also inhibit the kinases that are more potently inhibited (>2-fold) by Bos-I compared with Dasatinib. (as identified in Table 2).

	Remaining Kinase activity (%)
	Bos-I	Erlotinib	Gefitinib	Lapatinib	Sunitinib
EGFR	3.84	4.21	2.97	8.02	89.17
HGK MAP4K4	1.03	76.48	97.78	111.21	12.44
MINK/MINK1	1.21	85.68	102.32	110.74	10.46
RET	18.94	48.57	76.94	99.77	3.43
ERBB4/HER4	1.53	61.41	24.15	11.19	94.81

Kinases inhibited by >50% are highlighted in red.